Trial Profile

A Phase II Clinical Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese/Overweight Chronic Kidney Disease (CKD) Population

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UBT 251 (Primary)
Indications Obesity; Renal failure
Focus Therapeutic Use
Sponsors United Bio-Technology (Hengqin)

Most Recent Events

21 Aug 2025 Status changed from recruiting to active, no longer recruiting.
04 Apr 2025 New trial record
24 Mar 2025 according to Novo-Nordisk media release,the company recently initiated a phase 2 trial for UBT251 in people with overweight or obesity in China.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com